GlassScriptPhysician profile
Kiran Kashyap
NPI 1134192115
$1,325.38
in general payments reported to CMS, 2019-2025
14 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $28.27 · 2021: $23.02 · 2022: $90.85 · 2023: $98.15 · 2024: $455 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $280.01 | 2024-2025 | |
| Medtronic, INC. | $256.42 | 2021-2025 | Onyx Frontier, Symplicity G3 |
| Amgen INC. | $187.03 | 2023-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $146.58 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $103.44 | 2023-2024 | Opticross, Avvigo Guidance System |
| Novartis Pharmaceuticals Corporation | $83.03 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $74.59 | 2024-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $41.01 | 2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Novo Nordisk INC | $39.99 | 2024 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.08 | 2020-2022 | |
| Abiomed | $20.73 | 2022 | |
| Merck Sharp & Dohme LLC | $18.35 | 2025 | Verquvo |
| Chiesi USA, INC. | $17.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiran Kashyap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.